首页> 外文期刊>Health Economics Review >Factors influencing the variation in GMS prescribing expenditure in Ireland
【24h】

Factors influencing the variation in GMS prescribing expenditure in Ireland

机译:影响爱尔兰GMS处方支出差异的因素

获取原文
       

摘要

Background Pharmaceutical expenditure growth is a familiar feature in many Western health systems and is a real concern for policymakers. A state funded General Medical Services (GMS) scheme in Ireland experienced an increase in prescription expenditure of 414 % between 1998 and 2012. This paper seeks to explore the rationale for this growth by investigating the composition (Anatomical Therapeutic Chemical (ATC) Group level 1 & 5) and drivers of GMS drug expenditure in Ireland in 2012. Methods A cross-sectional study was carried out on the Health Service Executive-Primary Care Reimbursement Service (HSE-PCRS) population prescribing database ( n ?=?1,630,775). Three models were applied to test the association between annual expenditure per claimant whilst controlling for age, sex, region, and the pharmacology of the drugs as represented by the main ATC groups. Results The mean annual cost per claimant was €751 (median?=?€211; SD?=?€1323.10; range?=?€3.27–€298,670). Age, sex, and regions were all significant contributory factors of expenditure, with gender having the greatest impact (β?=?0.107). Those aged over 75 (β =1.195) were the greatest contributors to annual GMS prescribing costs. As regards regions, the South has the greatest cost increasing impact. When the ATC groups were included the impact of gender is diluted by the pharmacology of the products, with cardiovascular prescribing (ATC ‘C’) most influential (β?=?1.229) and the explanatory power of the model increased from 40 % to 60 %. Conclusion Whilst policies aimed at cost containment (co-payment charges; generic substitution; reference pricing; adjustments to GMS eligibility) can be used to curtail expenditure, health promotional programs and educational interventions should be given equal emphasis. Also policies intended to affect physicians’ prescribing behaviour include guidelines, information (about price and less expensive alternatives) and feedback, and the use of budgetary restrictions could yield savings in Ireland and can be easily translated to the international context.
机译:背景技术医药支出的增长是许多西方卫生系统所熟悉的特征,也是决策者真正关心的问题。在1998年至2012年之间,爱尔兰由国家资助的普通医疗服务(GMS)计划的处方药支出增加了414%。本文旨在通过研究其组成(解剖治疗化学(ATC)组1级, &&5)和2012年爱尔兰GMS药品支出的驱动因素。方法对卫生服务执行机构-初级保健报销服务(HSE-PCRS)人群处方数据库(n = 1630775)进行了横断面研究。应用了三个模型来测试每个索赔人的年度支出,同时控制年龄,性别,地区和主要ATC组代表的药物药理学之间的关联。结果每个索赔人的平均年成本为751欧元(中位数= 211欧元;标准差= 1323.10欧元;范围= 3.27欧元至298,670欧元)。年龄,性别和地区都是支出的重要促成因素,性别影响最大(β= 0.107)。年龄超过75岁(β= 1.195)的人是年度GMS处方费用的最大贡献者。在地区方面,南方对成本增加的影响最大。当将ATC组包括在内时,性别的影响会被产品的药理作用所稀释,其中心血管处方(ATC'C')最有影响(β?=?1.229),该模型的解释力从40%增加至60 %。结论尽管旨在控制成本的政策(共同支付费用;通用替代;参考价格;对GMS资格的调整)可以用来减少支出,但应同时重视健康促进计划和教育干预措施。旨在影响医师开处方行为的政策还包括指南,信息(关于价格和价格较低的替代品)和反馈,使用预算限制可以在爱尔兰节省开支,并且可以轻松地转化为国际背景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号